Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration

(Updated 3/12/22) A substance in the body called Vascular Endothelial Growth Factor (VEGF) is responsible for the growth of new blood vessels. It promotes this growth by stimulating the endothelial cells, which form the walls of the vessels and transport nutrients and oxygen to the tissues. Evidence shows that when the retinal pigment epithelial (RPE) [Read More]

New Treatment for Dry AMD Using HuCNS Stem Cells

by Dan Roberts February 2, 2012 StemCells, Inc. announced on February 2, 2012 that the FDA has authorized a Phase I/II clinical trial of a new method using stem cells from the brain to prevent degeneration of the macula in dry AMD patients. Purified human neural stem cells (HuCNS-SC) will be administered by a single [Read More]

Brachytherapy May Reduce Burden of Treatment and Further Improve Visual Acuity

(Updated August 26, 2020) San Francisco, CA (PRWEB) October 27, 2009 — NeoVista, Inc. made public at the American Academy of Ophthalmology meeting the company’s interim study results from the preliminary study MERITAGE-I. The study was designed to examine the company’s novel epimacular brachytherapy procedure when used in patients that require chronic anti-VEGF treatment for [Read More]